Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
University of Pennsylvania, Philadelphia, PA.
Liver Transpl. 2019 Jun;25(6):870-880. doi: 10.1002/lt.25454. Epub 2019 Apr 25.
We hypothesize that the prevalence of chronic kidney disease (CKD) among patients with cirrhosis has increased due to the increased prevalence of CKD-associated comorbidities, such as diabetes. We aimed to assess the characteristics of hospitalized patients with cirrhosis with CKD and its impact on renal and patient outcomes. The North American Consortium for the Study of End-Stage Liver Disease (NACSELD) prospectively enrolled nonelectively admitted patients with cirrhosis and collected data on demographics, laboratory results, in-hospital clinical course, and postdischarge 3-month outcomes. CKD positive (CKD+) patients, defined as having an estimated glomerular filtration rate (eGFR; Modification of Diet in Renal Disease-4 variable formula) of ≤60 mL/minute for >3 months, were compared with chronic kidney disease negative (CKD-) patients for development of organ failures, hospital course, and survival. There were 1099 CKD+ patients (46.8% of 2346 enrolled patients) who had significantly higher serum creatinine (2.21 ± 1.33 versus 0.83 ± 0.21 mg/dL in the CKD- group) on admission, higher prevalence of nonalcoholic steatohepatitis cirrhosis etiology, diabetes, refractory ascites, and hospital admissions in the previous 6 months compared with the CKD- group (all P < 0.001). Propensity matching (n = 922 in each group) by Child-Pugh scores (9.78 ± 2.05 versus 9.74 ± 2.04, P = 0.70) showed that CKD+ patients had significantly higher rates of superimposed acute kidney injury (AKI; 68% versus 21%; P < 0.001) and eventual need for dialysis (11% versus 2%; P < 0.001) than CKD- patients. CKD+ patients also had more cases of acute-on-chronic liver failure as defined by the NACSELD group, which was associated with reduced 30- and 90-day overall survival (P < 0.001 for both). A 10 mL/minute drop in eGFR was associated with a 13.1% increase in the risk of 30-day mortality. In conclusion, patients with CKD should be treated as a high-risk group among hospitalized patients with cirrhosis due to their poor survival, and they should be monitored carefully for the development of superimposed AKI.
我们假设,由于与慢性肾脏病相关的合并症(如糖尿病)的患病率增加,肝硬化患者中慢性肾脏病的患病率有所增加。我们旨在评估患有慢性肾脏病的肝硬化住院患者的特征及其对肾脏和患者结局的影响。北美终末期肝病研究联盟(NACSELD)前瞻性地招募了非选择性住院的肝硬化患者,并收集了人口统计学、实验室结果、住院临床过程和出院后 3 个月结局的数据。将慢性肾脏病阳性(CKD+)患者定义为肾小球滤过率(eGFR;通过改良肾脏病饮食研究-4 变量公式计算)持续>3 个月≤60 mL/min 的患者,与慢性肾脏病阴性(CKD-)患者进行比较,以评估器官衰竭、住院过程和生存情况。共有 1099 名 CKD+患者(2346 名入组患者中的 46.8%),与 CKD-组相比,入院时血清肌酐水平明显升高(2.21±1.33 比 0.83±0.21 mg/dL),非酒精性脂肪性肝炎肝硬化病因、糖尿病、难治性腹水和 6 个月内住院的比例更高(所有 P 值均<0.001)。通过 Child-Pugh 评分(9.78±2.05 比 9.74±2.04,P=0.70)进行倾向评分匹配(每组 922 例)后发现,CKD+患者的急性肾损伤(AKI)发生率(68%比 21%;P<0.001)和最终需要透析的比例(11%比 2%;P<0.001)均显著高于 CKD-患者。CKD+患者中,NACSELD 组定义的慢性肝衰竭急性加重(ACLF)病例更多,与 30 天和 90 天总生存率降低相关(均 P<0.001)。eGFR 下降 10 mL/min 会导致 30 天死亡率增加 13.1%。总之,由于患有慢性肾脏病的肝硬化患者生存较差,应将其视为住院肝硬化患者中的高危人群,应密切监测其急性肾损伤的发生情况。